World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
32626
World Ranking
15913
National Ranking
529

Danny Rischin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Danny Rischin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 441 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Danny Rischin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Danny Rischin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2021 - Fellow of the Australian Academy of Health and Medical Science

Overview

Danny Rischin is a researcher affiliated with the Peter MacCallum Cancer Centre in Australia. Their work primarily focuses on oncology, with significant contributions in subfields such as otorhinolaryngology, epidemiology, pulmonary and respiratory medicine, and immunology.

Their research covers a range of topics, including:

  • Head and Neck Cancer Studies
  • Cancer Immunotherapy and Biomarkers
  • Nonmelanoma Skin Cancer Studies
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Lung Cancer Treatments and Mutations
  • Immunotherapy and Immune Responses

Danny Rischin has an extensive publication record in several high-profile venues, notably:

  • Journal of Clinical Oncology
  • International Journal of Radiation Oncology*Biology*Physics
  • Annals of Oncology
  • Oral Oncology
  • SKIN The Journal of Cutaneous Medicine

Significant papers featuring Rischin include:

  • "Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing," 2020, Journal for ImmunoTherapy of Cancer
  • "Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial," 2020, The Lancet Oncology
  • "Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study," 2022, Journal of Clinical Oncology
  • "Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma," 2022, New England Journal of Medicine
  • "Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial," 2023, The Lancet Oncology

Frequent collaborators with Rischin include:

  • Matthew G. Fury
  • Brett Hughes
  • Kevin J. Harrington
  • Mathias Bressel
  • Makoto Tahara

In 2021, Danny Rischin was recognized as a Fellow of the Australian Academy of Health and Medical Science.

Best Publications

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

    Michael R. Migden;Danny Rischin;Chrysalyne D. Schmults;Alexander Guminski

  • Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

    Danny Rischin;Richard J. Young;Richard Fisher;Stephen B. Fox

  • Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02

    Lester J. Peters;Brian O'Sullivan;Jordi Giralt;Thomas J. Fitzgerald

  • Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02

    Danny Rischin;Rodney J. Hicks;Richard Fisher;David Binns

  • Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non–Small-Cell Lung Cancer

    Michael P. Mac Manus;Rodney J. Hicks;Jane P. Matthews;Allan McKenzie

  • Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition

    Joan Albanell;Federico Rojo;Steve Averbuch;Andrea Feyereislova

  • Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

    Danny Rischin;Lester J. Peters;Brian O'Sullivan;Jordi Giralt

  • Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

    J. Simon W. Stewart;Ezra E.W. Cohen;Lisa Licitra;Carla M.L. Van Herpen

  • Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

    Michael R Migden;Nikhil I Khushalani;Anne Lynn S Chang;Karl D Lewis

  • Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.

    Benjamin Solomon;Benjamin Solomon;Richard J Young;Danny Rischin

  • Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)

    Danny Rischin;Lester Peters;Richard Fisher;Andrew Macann

  • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

    S. N. Holden;S. G. Eckhardt;R. Basser;R. de Boer

  • F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.

    Michael P. Mac Manus;Rodney J. Hicks;David L. Ball;Victor Kalff

  • Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer

    Sandro V. Porceddu;Elizabeth Jarmolowski;Elizabeth Jarmolowski;Rodney J. Hicks;Rob Ware

  • Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

    Jeremy D. Shapiro;Michael J. Millward;Danny Rischin;Michael Michael

  • A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.

    Michael Friedlander;Kenneth C. Hancock;Danny Rischin;Mark J. Messing

  • The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer.

    June Corry;Lester J. Peters;Ieta D' Costa;Alvin D. Milner

  • Head and Neck Squamous Cell Carcinoma

    Richard J. Young;Danny Rischin;Richard Fisher;Grant A. McArthur

Frequent Co-Authors

Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre
Benjamin Solomon
Benjamin Solomon Peter MacCallum Cancer Centre
Lester J. Peters
Lester J. Peters Peter MacCallum Cancer Centre
Grant A. McArthur
Grant A. McArthur Peter MacCallum Cancer Centre
John R. Zalcberg
John R. Zalcberg Monash University
Michael A. Quinn
Michael A. Quinn International Gynaecological Cancer Society
Stephen B. Fox
Stephen B. Fox Peter MacCallum Cancer Centre
Lisa Licitra
Lisa Licitra University of Milan
Quynh-Thu Le
Quynh-Thu Le Stanford University
Alexander Dobrovic
Alexander Dobrovic University of Melbourne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens diverse opportunities beyond the traditional MD route. Many students consider alternative pathways and specialized online programs to advance their careers in healthcare.

Nursing professionals can expand their expertise through asn to fnp bridge programs, allowing a streamlined transition from Associate Degree in Nursing to Family Nurse Practitioner roles. For those looking to further nursing education without the hands-on clinical requirements, online rn to bsn programs no clinicals offer flexibility and convenience.

Healthcare management is another promising avenue. If you aspire to lead healthcare organizations, pursuing one of the best mha programs online, especially those accredited by CAHME, is a strong choice.

Additionally, an online degree nutrition can set the stage for careers in dietetics, wellness coaching, or public health. These varied pathways enable students to match their interests with high-demand healthcare fields, while enjoying the flexibility of online learning.

Best Scientists Citing Danny Rischin

Trending Scientists

Recently Published Articles